

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

202020Orig1s000

Trade Name: Rayos

Generic Name: prednisone

Sponsor: Horizon Pharma, Inc.

Approval Date: July 26, 2012

Indications: For allergic, endocrine, gastrointestinal, neoplastic, specific infectious, nervous system, ophthalmic, related organ transplantation, renal, and rheumatologic conditions; and dermatologic, hematologic, and pulmonary diseases.

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	
Labeling	X
REMS	
Summary Review	X
Officer/Employee List	X
Office Director Memo	
Cross Discipline Team Leader Review	X
Medical Review(s)	X
Chemistry Review(s)	X
Environmental Assessment	
Pharmacology Review(s)	X
Statistical Review(s)	X
Microbiology Review(s)	
Clinical Pharmacology/Biopharmaceutics Review(s)	X
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	X
Proprietary Name Review(s)	X
Administrative/Correspondence Document(s)	X

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:
202020Orig1s000

APPROVAL LETTER



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 202020

NDA APPROVAL

Horizon Pharma, Inc.
1033 Skokie Boulevard,
Suite 355
Northbrook, IL 60062

Attention: Timothy P. Walbert,
Chairman, President, and CEO

Dear Mr. Walbert:

Please refer to your New Drug Application (NDA) dated September 26, 2011, received September 26, 2011, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, for Rayos (prednisone) delayed release tablet 1 mg, 2 mg, 5 mg.

We acknowledge receipt of your amendments dated December, 22, and 29, 2011 and January 20, 23, and 31, February 1, and 2, March 21, April 9, and 13, May 4, and 9, June 6, 25, and 27, and July 18, 20, and 24, 2012.

This new drug application provides for the use of Rayos (delayed release prednisone) for allergic, endocrine, gastrointestinal, neoplastic, specific infectious, nervous system, ophthalmic, related organ transplantation, renal, and rheumatologic conditions; and dermatologic, hematologic, and pulmonary diseases.

We have completed our review of this application, as amended. It is approved effective on the date of this letter, for use as recommended in the agreed-upon labeling text, and with the minor editorial revisions listed below/indicated on the enclosed labeling:

1. Replaced, “**Initial U.S. Approval: [year]**”, with “**Initial U.S. Approval: [1955]**”
2. Replaced, “**Revised: [m/year]**”, with “**Revised: [July/2012]**”

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling text for the package insert. Information on

submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and container labels that are identical to the carton and immediate container labels submitted on July 20, 2012 as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled “Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008).” Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Carton and Container Labels for approved NDA 202020.**” Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

This product is appropriately labeled for use in all relevant pediatric populations. Therefore, no additional pediatric studies are needed at this time.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

EXPIRATION DATING PERIOD

The proposed expiry of thirty (30) months for products when stored at 25°C, with excursions permitted to 15 – 30°C (59 – 86°F), is granted.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Michelle Jordan Garner, Regulatory Project Manager, at (301) 796-4786.

Sincerely,

{See appended electronic signature page}

Badrul A. Chowdhury, MD, PhD
Director
Division of Pulmonary, Allergy, and
Rheumatology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE(S):

Content of Labeling
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

LYDIA I GILBERT MCCLAIN

07/26/2012

Deputy Division Director, signing for Dr Badrul Chowdhury